Rudolph Navari to Remission Induction
This is a "connection" page, showing publications Rudolph Navari has written about Remission Induction.
Connection Strength
0.087
-
Should palonosetron be a preferred 5-HT3 receptor antagonist for chemotherapy-induced nausea and vomiting? An updated systematic review and meta-analysis. Support Care Cancer. 2018 Aug; 26(8):2519-2549.
Score: 0.033
-
Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review. Support Care Cancer. 2016 Feb; 24(2):1001-1008.
Score: 0.028
-
Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer. 2002 Jan 01; 94(1):25-36.
Score: 0.011
-
Efficacy and safety of different doses of granisetron for the prophylaxis of cisplatin-induced emesis. Support Care Cancer. 1997 Jan; 5(1):31-7.
Score: 0.008
-
Double-blind, randomized comparison of the antiemetic efficacy of intravenous dolasetron mesylate and intravenous ondansetron in the prevention of acute cisplatin-induced emesis in patients with cancer. Dolasetron Comparative Chemotherapy-induced Emesis Prevention Group. J Clin Oncol. 1996 Aug; 14(8):2242-9.
Score: 0.007